The global burden of malaria remains substantial. Circumsporozoite protein (CSP) has been
demonstrated to be an effective target antigen, however, improvements that offer more …

Antibodies to Circumsporozoite protein (CSP) confer protection against controlled human
malaria infection (CHMI) caused by the parasite Plasmodium falciparum. Although CSP is …

Background Fully efficient vaccines against malaria pre-erythrocytic stage are still lacking.
The objective of this dose/adjuvant-finding study was to evaluate the safety, reactogenicity …

Malaria caused by Plasmodium falciparum continues to threaten millions of people living in
the tropical parts of the world. A vaccine that confers sterile and life-long protection remains …

Plasmodium falciparum circumsporozoite protein (CSP) is a major sporozoite surface
protein and a key target of pre-erythrocytic malaria subunit vaccines. A full-length …

There is hope that 2023 could bring regulatory approval, licensing, and implementation
programs for safe and effective adjuvanted vaccines to prevent malaria. Clinical trials …

Background Non-human primates, such as the rhesus macaques, are the preferred model
for down-selecting human malaria vaccine formulations, but the rhesus model is expensive …

Background The P. falciparum chimeric protein 2.9 (PfCP-2.9) consisting of the sequences
of MSP1-19 and AMA-1 (III) is a malaria vaccine candidate that was found to induce …

BACKGROUND Malaria transmission-blocking vaccines aim to interrupt the transmission of
malaria from one person to another. METHODS The candidates R0. 6C and ProC6C share …

BACKGROUND: Immunization with RTS, S/AS02 consistently protects some vaccinees
against malaria infection in experimental challenges and in field trials. A brief immunization …